- Home
- AMRN
as 05-30-2025 4:00pm EST
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
| Founded: | 1989 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 2 |
| Market Cap: | 216.0M | IPO Year: | 1993 |
| Target Price: | $7.00 | AVG Volume (30 days): | 76.9K |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.08 - $17.58 | Next Earning Date: | 05-07-2025 |
| Revenue: | $214,112,000 | Revenue Growth: | -22.83% |
| Revenue Growth (this year): | -17.25% | Revenue Growth (next year): | 5.97% |
Latest Amarin Corporation plc News
AMRN Breaking Stock News: Dive into AMRN Ticker-Specific Updates for Smart Investing
Zacks
4 days ago
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year?
Simply Wall St.
23 days ago
Earnings Update: Amarin Corporation plc (NASDAQ:AMRN) Just Reported And Analysts Are Boosting Their Estimates
Zacks
25 days ago
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y
Simply Wall St.
25 days ago
Amarin First Quarter 2025 Earnings: Misses Expectations
GuruFocus.com
25 days ago
Amarin Corp PLC (AMRN) Q1 2025 Earnings Call Highlights: Strategic Global Expansion Amidst ...
Associated Press Finance
a month ago
Amarin: Q1 Earnings Snapshot
GlobeNewswire
a month ago
Amarin Reports First Quarter 2025 Financial Results
GuruFocus.com
a month ago
Standex International Corp (SXI) Q3 2025 Earnings Call Highlights: Record Margins and Strategic ...
Compare AMRN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AMRN Amarin Corporation plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.